ArticlePloS one2025
Change in D3Cr muscle mass in oldest old men and its association with changes in grip strength and walking speed.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia.Advances in therapy · 2026Review
- Discovery of key surface electromyography features during walking for discerning high and low muscle mass using machine learning analysis.Scientific reports · 2026Article
- Myosteatosis: an emerging biomarker of aging.Frontiers in aging · 2026Review
- A simplified definition of sarcopenia: muscle mass/body weight.The journal of nutrition, health & aging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe use of lean soft tissue (LST) mass as a surrogate measurement of skeletal muscle mass (SMM) has led to the conclusion that muscle loss is poorly related to functional decline. We hypothesized that when using a more accurate measure of SMM determined by D3-creatine dilution (D3Cr), longitudinal changes in SMM will be similar in magnitude to changes in strength and physical performance and that skeletal muscle mass will partially mediate the relationship of age with these outcomes.
methodsWe measured change in D3Cr muscle mass (kg), handgrip strength (kg), and 6m walk speed (m/s) in 208 men from the Osteoporotic Fractures in Men Study (85.2 ± 4.3 years) over an average of 6.1 years follow-up. Mixed linear effects models adjusted for potential confounders were used to examine the relationship of changes in D3Cr muscle mass with changes in grip strength and walking speed.
resultsAnnual losses of D3Cr muscle mass, grip strength, and walking speed were 2.1%, 2.2%, and 2.6%, respectively (p < 0.001). Each additional kg loss in D3Cr muscle mass was associated with a 0.55 kg loss in grip strength and a 0.01 m/s loss in walking speed independent of changes in age (p < 0.001). 41.3% and 22.4% of the relationship between age and loss of grip strength and walking speed, respectively, was attributed to loss of D3Cr muscle mass (p < 0.001).
conclusionSkeletal muscle mass may have a more important role than previously considered and should not be overlooked as a potentially modifiable determinant in the loss of strength and performance in older age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.